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Abstract
Purpose Therapeutic drug monitoring of patients receiving
once daily aminoglycoside therapy can be performed using
pharmacokinetic (PK) formulas or Bayesian calculations.
While these methods produced comparable results, their per-
formance has never been checked against full PK profiles. We
performed a PK study in order to compare both methods and
to determine the best time-points to estimate AUC0-24 and
peak concentrations (Cmax).
Methods We obtained full PK profiles in 14 patients receiving
a once daily aminoglycoside therapy. PK parameters were
calculated with PKSolver using non-compartmental methods.
The calculated PK parameters were then compared with pa-
rameters estimated using an algorithm based on two serum
concentrations (two-point method) or the software TCIWorks
(Bayesian method).
Results For tobramycin and gentamicin, AUC0-24 and Cmax
could be reliably estimated using a first serum concentration
obtained at 1 h and a second one between 8 and 10 h after start
of the infusion. The two-point and the Bayesian method
produced similar results. For amikacin, AUC0-24 could reli-
ably be estimated by both methods. Cmax was underestimated
by 10–20% by the two-point method and by up to 30%with a
large variation by the Bayesian method.
Conclusions The ideal time-points for therapeutic drug mon-
itoring of once daily administered aminoglycosides are 1 h
after start of a 30-min infusion for the first time-point and 8–
10 h after start of the infusion for the second time-point.
Duration of the infusion and accurate registration of the
time-points of blood drawing are essential for obtaining pre-
cise predictions.
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Once-daily dosing . Pharmacokinetics
Introduction
Aminoglycosides were among the first antibiotics introduced
into clinics [1] and are still used widely, mainly in the treat-
ment of severe gram-negative infections [2]. Rapid
concentration-dependent killing, low prevalence of bacterial
resistance, a marked post-antibiotic effect, and low costs are
the main causes for their continued use [2, 3]. During the last
two decades, extended dosing interval strategies, in particular,
once-daily dosing (ODD), are increasingly recommended and
used [4]. The possible therapeutic advantage of aminoglyco-
side ODD over conventional multiple daily dosing is a lower
incidence of renal and ototoxicity with equal or better efficacy
[5–9]. Importantly, the desired ratio of maximal drug concen-
tration (Cmax) over the minimal inhibitory concentration
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(MIC) ofmore than 8, which is needed for good efficacy of the
aminoglycosides [3, 10], can be reached easily with ODD.
Since aminoglycoside toxicity, in particular, nephrotoxicity,
has been associatedwith increased trough concentrations (Cmin)
and duration of treatment [11, 12], ODD may also help to
decrease aminoglycoside toxicity. Further advantages of ami-
noglycoside ODD include straightforward dosage calculation,
decreased personnel time, possibly fewer assays for therapeutic
drug monitoring (TDM), and, as a result, lower costs [13].
However, although ODD has been assessed in many clinical
trials, there has been little uniformity regarding the best dosing
and monitoring strategy for ODD. TDM based on individual
pharmacokinetic values can reduce aminoglycoside toxicity
and at the same time allow the administration of a larger
cumulated dose [5].
The traditional concept of Cmax and Cmin measurement
may not be appropriate for ODD of aminoglycosides for
several reasons. In patients with normal renal function, the
serum concentrations at 24 h usually are below the lower limit
of quantification (LLOQ) of the routinely used immunoassays
[13, 14]. Furthermore, measurement of trough concentrations
would delay treatment adjustments for at least one dose inter-
val [15]. Measurement of the peak concentration ensures that
the Cmax is sufficiently above the MIC of the pathogen and is
therefore important to judge the efficacy of the treatment. On
the other hand, Cmax is not an ideal marker for toxicity, which
is best reflected by the area under the curve (AUC) and the
trough serum concentration [16].
Taking into account these considerations, Begg et al. [13,
14] proposed a method of aminoglycoside ODD drug moni-
toring based on a target AUC, which is equivalent to the AUC
achieved in adult patients with conventional multiple daily
dose regimens over 24 h. They proposed to determine two
serum concentrations, the first at approximately 0.5 h after the
end of the infusion and the second at least 2.5 but not longer
than five expected half-lives after the application. After esti-
mation of AUC0-24 from these two values assuming one-
compartment pharmacokinetics, dose adjustment is based on
the ratio of calculated to target AUC using linear extrapolation
[13, 14]. The suitability of this method has been investigated
in approximately 100 patients; in this study, Begg’s method
was reported to be practical [17]. With some limitations, this
method can also be used for aminoglycoside dosing in patients
with mild to moderate renal dysfunction. In patients with
moderate to severe renal dysfunction, it may be necessary to
increase the dose interval to more than 24 h in order to reach
sufficiently high peak serum concentrations and avoid accu-
mulation. However, dose intervals longer than 24 h have so far
not been assessed in clinical trials.
An alternative method to Begg’s method is the Bayesian
approach [18], which, however, requires computation assis-
tance. The comparability of the Bayesian method and Begg’s
method has recently been investigated and published for
gentamicin by Wong et al. [19]. However, to our knowledge,
so far, neither Begg’s method nor the Bayesian method has
been checked against full pharmacokinetic (PK) profiles.
We therefore obtained full PK profiles in 14 patients treated
once daily with an aminoglycoside, allowing us to address the
following questions: (1) How reliably can Cmax and AUC0-24
of once-daily dosed aminoglycosides be estimated using
mathematical models (i.e., Begg’s algorithm [two-point meth-
od] or a Bayesian method) in comparison to determinations
using full PK profiles? (2) Which time-points of the kinetic
profile provide the best estimate for Cmax and AUC0-24 ?
Methods
Study design
Fourteen patients with once-daily aminoglycoside dosing and
normal or impaired (but stable) renal function over the last
3 days were prospectively included at the University Hospital
of Basel. Aminoglycosides were dosed according to clinical
routine. Patients with tobramycin therapy received 5–8 mg/kg
bodyweight and patients with gentamicin therapy 2–3 mg/kg
bodyweight. Patients with amikacin (mostly patients with
febrile neutropenia) were treated according to an internal
protocol with a starting dose of 1,000 mg amikacin. Amino-
glycosides were diluted in normal saline and infused intrave-
nously over 30 min. Blood samples (serum) for the PK pro-
files were collected at the following time-points: tstart=before
start of the aminoglycoside infusion (baseline), tend=at end of
aminoglycoside infusion (30 min) and 45min, 1, 2, 4, 6, 8, 12,
and 24 h after the start of the infusion. Blood samples were
either obtained by a peripheral intravenous line placed at the
contralateral side of the aminoglycoside infusion or by an
aminoglycoside free lumen of a central venous line. The study
was approved by the Ethics Committee of Basel and was
conducted in accordance with the Declaration of Helsinki
and the International Conference on Harmonization Good
Clinical Practice guidelines. All patients gave written in-
formed consent.
Analytics
Aminoglycoside serum levels were measured by the Clinical
Chemistry laboratory of the University Hospital Basel using
different commercially available methods. Amikacin was
measured using the Roche Kinetic Interaction of Microparti-
cles in Solution assay AMIK2, which has a LLOQ of 0.8 mg/
L. Tobramycin was measured using the Roche Enzyme Mul-
tiplied Immunoassay Technique assay TOBR2 with an LLOQ
of 0.33 mg/L. The assays for gentamicin had changed during
the study period. From May 2010 until August 2010, genta-
micin was measured using a fluorescence polarization
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immunoassay (Abbott, USA, LLOQ 0.3 mg/L). From Sep-
tember 2010 until July 2011, gentamicin was measured using
a cloned enzyme donor immunoassay (Thermofisher, USA,
LLOQ, 0.3 mg/L). From July 2011 until December 2011,
gentamicin was measured using a chemiluminescence micro-
particle assay (Abbott, USA, LLOQ 0.3 mg/L).
Pharmacokinetic analysis
PK parameters obtained from full PK profiles
(labeled as Xobs)
Serum concentration data were analyzed using the Excel
add-in PKSolver from Zhang et al. [20]. For the calcu-
lation of the AUC from time of dosing to the last
observable concentration (AUC0-last
obs), the “mixed lin-
ear up/log down” model was chosen. As the last ob-
servable concentration (Clast
obs) was not always identical
to the concentration at 24 h (C24
obs), the latter had to be
calculated as follows (Eq. 1):
Cobs24 ¼ Cobslast ⋅e ‐k
obs
e ⋅ t24−tlastð Þ½  ð1Þ
where ke
obs was the elimination rate constant, given by
PKSolver. AUC from 0 to 24 h was then calculated as follows
(Eq. 2):
AUCobs0−24 ¼ AUCobs0−last þ
Cobslast − C
obs
24
ln Cobslast
 
− ln Cobs24
  t24‐tlastð Þ ð2Þ
Tmax
obs and Cmax
obs were obtained directly from observed
concentration–time data.
PK parameters obtained by two-point estimation
(labeled as X2-point)
PK parameters were calculated using two concentration-time
point pairs (t1/C1, t2/C2) according to the algorithm proposed
by Begg et al. [13] with a modification for AUC0-24. The
estimated elimination rate constant (ke
2-point) is given by
(Eq. 3):
k2‐pointe ¼
ln C1ð Þ  ln C2ð Þ
t2  t1 ð3Þ
With this, the concentration at end of infusion (Cend
2-point)
is (Eq. 4):
C2‐pointend ¼ C1 ⋅ e k
2‐point
e ⋅ tendt1ð Þ½  ð4Þ
where tend is the infusion time. The concentration at the end of
the dosing interval (C24
2-point) is (Eq. 5):
C2‐point24 ¼ C2 ⋅e ‐k
2‐point
e t24t2ð Þ½  ð5Þ
With this, the AUC0-24
2-point was calculated as follows
(Eq. 6):
AUC2‐point024 ¼ AUC0end þ AUCend24 ¼
C2‐pointend ⋅ tend
2
þ C
2‐point
end  C2‐point24
k2‐pointe
ð6Þ
While we prefer to calculate AUC0-end, Begg et al. assumed
that AUC0-end was 6.5 % of AUCend-24 [13].
These PK parameters were estimated using different time-
point combinations (1 and 6 h, 1 and 8 h, 1 and 12 h, 2 and 6 h,
2 and 8 h, 2 and 12 h), and the estimates (X2-point) were then
compared with the calculated parameters based on full PK
profiles (Xobs).
PK parameters obtained by Bayesian estimation
(labeled as XTCI)
Bayesian analysis was performed using the software package
TCIWorks (freely available at www.tciworks.info). For
tobramycin and gentamicin, the built-in model “Gentamicin/
Tobramycin” was used, and for amikacin, the model
“Amikacin for Adults”. Both models were used in the one-
compartment mode. AUC0-24
TCI and Cmax
TCI were deter-
mined using the same time-point combinations as for the
Excel-based two-point estimation (i.e., 1 and 6 h, 1 and 8 h,
1 and 12 h, 2 and 6 h, 2 and 8 h, 2 and 12 h). The estimates
(XTCI) were then compared with the PK parameters based on
full PK profiles (Xobs).
Graphical and statistical analyses
Figures were drawn with GraphPad Prism 6.02 for Windows.
Due to the small sample size, statistical significance testing
was not performed.
Results
The baseline characteristics of the 14 patients are shown in
Table 1. Seven patients were treated with tobramycin, three
with gentamicin, and four with amikacin; all of them were
managed using Begg’s algorithm. Five patients were clinically
and microbiologically cured and could leave the hospital,
whereas nine improved clinically and could be transferred to
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another hospital. None of the patients developed a significant
change in renal function during the hospitalization. With the
exception of patient 105 (see ID number in Table 1), the
estimated GFR was >90 ml/min/1.73 m2 (CKD-EPI
formula). Thus, our results can be generalized only to patients
with normal renal function.
Figure 1 shows the PK profiles according to the adminis-
tered aminoglycoside. As can be seen, most semi-logarithmic
plots are not linear. Some profiles show a bi-exponential
shape, and some appear to be even tri-exponential. For Bayes-
ian analyses, this could be taken into account by choosing an
appropriate model. In contrast, the two-point estimation ac-
cording to the algorithm proposed by Begg et al. is based on a
one-compartment model with linear elimination [13]. It could
therefore be expected that, in the case of one compartment
models, the estimation of Cmax and AUC is going to depend
on the two time-points chosen for their calculation.
Figure 2 shows the accuracy of the two-point estimation
and the Bayesian estimation (TCI method) for different time-
point combinations for Cmax. The values shown in the figure
are the ratios of the calculated and the corresponding observed
values.
For tobramycin and gentamicin, the mean estimates were
8 % to 26% lower than the corresponding observed values for
all time point combinations. The differences between the two-
point and Bayesian estimations were only small. The variation
tended to be more accentuated for the two-point estimation
than for the Bayesian method and became larger when the first
determination was shifted from 1 to 2 h after start of the
infusion.
For amikacin, the mean estimates were 15 to 35 % lower
than the observed values with an acceptable variability for the
two-point method estimates, whereas the variability was much
higher for the Bayesian estimates. The large variability for the
Bayesian estimates was mainly due to patient 107, who had
ratios between 1.72 (for 1/6 h) and 2.05 (for 2/6 h). Patient 107
had the highest eGFR, resulting in a high elimination rate and
therefore a high estimate of Cmax with the Bayesian method.
The AUC estimations showed a different picture compared
with the estimations for Cmax (Fig. 3). For all three drugs, the
estimated AUC0-24 increased with the interval between the
two time-points. In contrast to the estimations for Cmax, the
choice of the first-time-point (1 vs. 2 h) was hardly relevant for
the estimation of the AUC0-24. The accuracy of the AUC0-24
estimation depended on the time-point of the second measure-
ment and the time interval between the two measurements.
Considering tobramycin, the time-point combinations 1/12 h
and 2/12 h were ideal for the two-point method. For the
Bayesian estimation, the combination 1/12 h was slightly
superior compared with the combination 2/12 h. For gentami-
cin, the combinations 1/8 h and 2/12 h were best for both
calculation methods. For amikacin, the combinations 1/8 h,
2/8 h, and 2/12 h gave the best results for both calculation
methods, but, similar to Cmax, the values for AUC0-24 showed
Table 1 Baseline characteristics of the patients included in the study
ID Age
[years]
Sex Weight
[kg]
eGFR [ml/min/
1.73 m2]
Therapy Dose
[mg]
Dose per kilogram
[mg/kg]
Infusion
time [min]
Diagnosis/indication
101 61 f 60 106 Tobramycin 380 6.3 45 Osteomyelitis; Pseudomonas aeruginosa,
Serratia liquefaciens
102 73 m 73 98 Tobramycin 560 7.7 35 Septic gonarthritis; P. aeruginosa
103 28 m 62 121 Tobramycin 420 6.8 35 Cystic fibrosis; P. aeruginosa, ESBL
105 65 m 80 72 Tobramycin 500 6.3 30 Pleural empyema; P. aeruginosa, Klebsiella
pneumoniae
108 49 m 82 109 Tobramycin 570 7.0 30 Spondylodiscitis; P. aeruginosa
112 74 m 90 129 Tobramycin 460 5.1 30 Wound infection after laminectomy;
P. aeruginosa
116 23 f 50 129 Tobramycin 280 5.6 32 Cystic fibrosis; P. aeruginosa
104 69 m 80 95 Gentamicin 240 3.0 30 Spondylodiscitis, epidural abscess;
Streptococcus mitis/oralis
109 67 f 68 96 Gentamicin 200 2.9 30 Aortic valve prosthesis endocarditis;
Staphylococcus epidermidis
114 61 m 110 92 Gentamicin 240 2.2 30 Aortic valve endocarditis
107 39 m 85 136 Amikacin 1,000 11.8 30 neutropenic fever
110 28 f 48 123 Amikacin 1,000 20.8 30 Tuberculosis; Mycobacterium tuberculosis
complex
111 26 m 94 117 Amikacin 1,000 10.6 25 Neutropenic fever
115 42 m 72 105 Amikacin 1,000 13.9 30 Neutropenic fever
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a large variation for the Bayesian estimates. Considering only
the mean values, the differences between the two calculation
methods were small.
In the clinical situation, the exact difference between the
estimated and the observed values is less relevant. The physi-
cian would rather like to knowwhether the treatment decision,
which is based on the described calculations, was correct. If
the estimated Cmax is within the target range (i.e., 15–25 mg/L
for tobramycin and gentamicin; 55–65 mg/L for amikacin)
and the AUC does not exceed the upper limit (100 mg/L*h for
gentamicin and tobramycin and 240mg/L*h for amikacin), no
dose adjustment is recommended. Otherwise, the dose is
adjusted using linear interpolation in order to reach the target
values. Table 2 illustrates the comparison for the estimated
and the observed values for Cmax for the 1/8 h time point and
the corresponding decisions which are based on the estimates.
The decisions are labeled “wrong” when another decision
would have been made based on the observed value. For the
two-point estimations, the decisions would have been correct
with the exception of patients 110 and 112. In patient 112, the
tobramycin dose would have been increased instead of main-
tained and in patient 110, the amikacin dose would have been
maintained instead of decreased. For the Bayesian estimation,
the decisions would have been correct except for patients 102
and 110. For patient 102, the dose would have been increased
instead of maintained and for patient 110, the dose would
have been maintained instead of decreased. As shown in
Electronic supplementary material Table 1, the combination
01/06 h showed a comparable performance like the combina-
tion 01/08 h, whereas the performance of the other combina-
tions (01/12 h, 02/06 h, 02/08 h, 02/12 h) was worse for both
calculation methods.
Fig. 1 Semilogarithmic plots of the PK profiles of the 14 patients sorted
by the aminoglycoside administered. Most profiles are not linear and
show a distribution and one to two elimination phases
Fig. 2 Ratios of the calculated and the observed values for Cmax. The
values are given individually and as the mean±90 % CI sorted per
aminoglycoside and also combined for all applications (pooled data).
The dashed horizontal lines indicate the limits of bioequivalence (0.8
and 1.25)
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Table 3 illustrates the comparison for the estimated and the
observed values for AUC0-24 for the 1/8 h time point and the
corresponding decisions which are based on the estimates. For
the two-point method, wrong decisions would have been
made for patients 101 and 112. For patient 101, the
tobramycin dose would have been maintained instead of
reduced and for patient 112, the tobramycin dose would have
been increased instead of maintained. For the Bayesian esti-
mation, only for patient 101 would a wrong decision
(tobramycin dose maintained instead of reduced) have been
made. The comparisons between the estimated and observed
values for AUC0-24 for the other time-point combinations are
shown in Electronic supplementary material Table 2. As ex-
pected, the best performance was achieved for the time points
with the longest interval between the measurements (1/12 h
and 2/12 h). The time points 1/8 h and 2/8 h were considered
to have an acceptable performance, whereas the error rate for
the time points 1/6 h and 2/6 h were considered to be too high.
Discussion
Our study shows that Cmax and AUC0-24 of once-daily dosed
aminoglycosides can be estimated reliably with a two-point
mono-compartmental method but that the results obtained
depend on the time-points chosen for the concentration mea-
surements. For the estimation of Cmax, the best time-point
combinations were 1/6–8 h and for AUC0-24 1-2/8–12 h after
Fig. 3 Ratios of the calculated
and the observed values for
AUC0-24. The values are given
individually and as the mean±
90 % CI sorted per
aminoglycoside and also
combined for all applications
(pooled data). The dashed
horizontal lines indicate the limits
of bioequivalence (0.8 and 1.25)
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start of the infusion. The accuracy of the prediction was
similar for the two-point and for the Bayesian method (target
concentration intervention software TCIWorks).
Using two (or more) serum drug concentrations to deter-
mine the next aminoglycoside dose has already been proposed
more than 10 years ago by Sawchuck and Zaske [21] as well
as by Begg et al. [13]. The usually recommended procedure is
to measure the aminoglycoside plasma concentration at two
time-points, the first up to 4 h after the end of the infusion and
the second 6–14 h after the end of the infusion [19]. The
current study shows that Cmax can be estimated more accu-
rately, if the first time-point is chosen early. On the other hand,
Table 2 Comparison of the estimated and observed values for Cmax for the time point combination 1/8 h
ID Therapy Dose Target Cmax Cmax
observed Cmax
2-point Decision Cmax
TCI Decision
[mg/24 h] [mg/L] [mg/L] [mg/L] [mg/L]
101 Tobramycin 380 15–25 19.0 17.2 Correct 17.9 Correct
102 Tobramycin 560 15–25 15.8 15.2 Correct 14.9 Wrong
103 Tobramycin 420 15–25 17.7 16.6 Correct 15.1 Correct
105 Tobramycin 500 15–25 20.8 19.0 Correct 20.3 Correct
108 Tobramycin 570 15–25 33.5 28.8 Correct 28.2 Correct
112 Tobramycin 460 15–25 16.0 13.7 Wrong 15.2 Correct
116 Tobramycin 280 15–25 19.0 15.2 Correct 15.0 Correct
104 Gentamicin 240 15–25 8.6 8.0 Correct 8.8 Correct
109 Gentamicin 200 15–25 12.5 11.3 Correct 11.2 Correct
114 Gentamicin 240 15–25 9.1 6.5 Correct 7.5 Correct
107 Amikacin 1,000 55–65 22.8
110 Amikacin 1,000 55–65 67.9 57.1 Wrong 64.6 Wrong
111 Amikacin 1,000 55–65 72.2
115 Amikacin 1,000 55–65 50.0 39.2 Correct 44.6 Correct
Values for Cmax were estimated using either the two-point method (Cmax
2-point ) or the Bayesian method (Cmax
TCI ) as described in Methods. Based on
these estimates, decisions were made according to the target values. If the decisions made based on the estimated values corresponded to those made
using the observed values, they were termed “correct”. If there was a disagreement between the decisions based on the estimated and the observed values,
they were termed “wrong”
Table 3 Comparison of the estimated and observed values for AUC0-24 for the time point combination 1/8 h
ID Therapy Dose Target AUC0-24 AUC0-24
observed AUC0-24
2-point Decision AUC0-24
TCI Decision
[mg/
24 h]
[mg/L * h] [mg/L * h] [mg/L * h] [mg/L * h]
101 Tobramycin 380 70–100 102 79.5 Wrong 81 Wrong
102 Tobramycin 560 70–100 95 84.1 Correct 77 Correct
103 Tobramycin 420 70–100 88 82.7 Correct 72 Correct
105 Tobramycin 500 70–100 173 165.2 Correct 157 Correct
108 Tobramycin 570 70–100 131 122.1 Correct 118 Correct
112 Tobramycin 460 70–100 74 68.4 Wrong 72 Correct
116 Tobramycin 280 70–100 44 46.9 Correct 45 Correct
104 Gentamicin 240 70–100 41 36.1 Correct 38 Correct
109 Gentamicin 200 70–100 55 55.2 Correct 53 Correct
114 Gentamicin 240 70–100 31 30.3 Correct 33 Correct
107 Amikacin 1,000 200–240 42
110 Amikacin 1,000 200–240 159 154.6 Correct 171 Correct
111 Amikacin 1,000 200–240 144
115 Amikacin 1,000 200–240 208 207.5 Correct 218 Correct
Values for AUC0-24 were estimated using either the two-point method (AUC0-24
2-point ) or the Bayesian method (AUC0-24
TCI ) as described in Methods.
Based on these estimates, decisions were made according to the target values. If the decisions made based on the estimated values corresponded to those
made using the observed values, they were termed “correct”. If there was a disagreement between the decisions based on the estimated and the observed
values, they were termed “wrong”
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the prediction of AUC0-24 depends more on the duration of the
interval between the two time-points. Accordingly, the best
time-points for the estimation of Cmax were 1/6–8 h and for
AUC0-24 1–2/8–12 h. Therefore, we propose to obtain the first
plasma sample 1 h after start of the infusion (duration of the
infusion 30 min) and the second one 8–10 h after start of the
infusion. Considering the typical half-life of 2–4 h for all
aminoglycosides, the second plasma sample would be obtain-
ed two to five half-lives after the start of the infusion. This is
consistent with Begg’s proposal, who recommended the de-
termination of aminoglycoside concentrations 0.5 h after the
end of the infusion and between 2.5 and 5 half-lives later,
whereby the infusion should be administered within 30 min
[13].
With our proposal considering the time-points of blood
sampling (1/8–10 h), the mean error of the AUC0-24 calculated
with the two-point method does not exceed ±10 % regardless
of the aminoglycoside administered, which appears to be
acceptable. The mean peak concentrations for tobramycin
and gentamicin underestimated the observed values by 10–
20%, which is also tolerable in our opinion. For amikacin, the
two-point method underestimated the mean Cmax by 22 %,
which may be due to the short half-life of this drug (Fig. 1).
The underestimation of Cmax by the two-point method can
partially be explained by the observation that all aminoglyco-
sides investigated showed a considerable distribution phase
lasting 1 to 2 h after termination of the infusion (Fig. 1). Since
it can be questioned whether the distribution phase contributes
to the antibacterial activity of the aminoglycosides, we pro-
pose to accept the calculated value at the end of the infusion as
Cmax, even if it underestimates the observed Cmax by up to
22 %. Since Cmax is related to efficacy (and not to toxicity if
AUC0-24 is within the target range), this approach guarantees
efficacy while minimizing toxicity.
An alternative method to the Excel method is the Bayesian
approach [18]. Bayesian methods are currently considered to
be the gold standard in therapeutic drug monitoring, but they
require computational assistance and are usually based on
pharmacokinetic data originating from different populations
than the individual patients studied. There are different com-
puter tools available to assist clinicians for Bayesian calcula-
tions for aminoglycosides [22]. One of these computer tools is
the target concentration intervention software package
TCIWorks, which is running under the Windows operating
system. The program is based on models from results of
previous pharmacokinetic studies and utilizes the creatinine
clearance (ClCr) as a surrogate of the aminoglycoside clear-
ance, since the systemic clearance of aminoglycosides corre-
lates with ClCr [19].
The comparability of the Bayesian method (TCI method)
with the two-point method has recently been investigated and
demonstrated for gentamicin by Wong et al. [19]. Our results
are consistent with those obtained by Wong et al., although
our study population was smaller than Wong’s. The
current study shows that the results of the two-point
and the Bayesian method are comparable also for
tobramycin. Regarding amikacin, the TCI method
tended to be less accurate, which was mainly due to
one patient with an exceptionally high ClCr. Regarding
amikacin, more data are therefore necessary to compare
the two methods for dose prediction.
It is important to realize that the time-points (start and end
of the infusion, withdrawal of blood samples) have to be
determined accurately; otherwise, the calculations can become
erroneous. Much effort has therefore to be made that these
time-points are recorded and transmitted accurately. An im-
portant point in this respect is the choice of the application
time, which determines the time-points when the two blood
samples have to be drawn. In our experience, best results are
obtained when the two blood samples are obtained during the
day shift and not during the night. If clinically possible, we
therefore advise to administer aminoglycosides in the morning
in order to obtain the second blood sample in the afternoon,
allowing the calculation of the next dose still during the day
shift. Another important point is the duration of the infusion,
which should be 30 min. Deviations in the duration of the
infusion could also lead to erroneous calculations, especially
considering Cmax.
The limited number of patients included is clearly a
weakness of the study, particularly for amikacin. Anoth-
er weakness is the fact that all patients included had a
normal or only slightly reduced renal function and were
not severely septic. The results of our study can there-
fore only be generalized to this patient population. Fur-
ther studies are necessary for dose predictions of ami-
noglycosides in special populations, e.g., septic patients
or patients with impaired renal function.
Conclusion
Our study indicates that the ideal time-points for therapeutic
drug monitoring of once daily administered aminoglycosides
are 1 h after start of a 30-min infusion for the first and 8–10 h
after start of the infusion for the second blood sample. With
these two time-points, Cmax as well as AUC0-24 can be esti-
mated reliably and can be used for determining the next dose,
either by the simple two-point method using a one-
compartment model or by the more sophisticated Bayesian
approach.
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